Neil Riordan PhD

Professional Site

  • Scientific Articles
  • Abstracts
  • Stem Cell Research
    • Heart Disease
    • Lupus
    • Mesenchymal Stem Cells
    • Pulmonary
  • Intellectual Property
  • Book Chapters
  • Invited Reviewer
  • Awards
Home Archives for nhriordan

Stage IV Lung Cancer Patient Still Benefiting from Dendritic Cell Vaccine 15 Years Later

Posted on June 12, 2014 Written by nhriordan 3 Comments

I received this forwarded email today from the nephew of a patient who was in our clinical trial in 1998-1999 using dendritic cells. We had tried to follow up with her but could not locate her due to a move.

The dendritic cell vaccine that was used on her was the subject of the patent cited below.

June 7, 2014

Dear Riordan Clinic Researchers

I am writing to you in regards to research that you did in 1998-1999. I know that in dealing with cancer patients you must encounter many sad stories, so I thought you would like to hear one with a happy ending. I have looked on your web page and I don’t see that you are still doing research on this project but I thought you would be interested in the results anyway…..maybe they will spark a new research project.

My mother passed away a while back and I have been going through her papers. She saved all the information on my aunt’s (her sister) cancer treatment so I can actually give you accurate details below.

In the fall of 1998 my Aunt, XXX XXXXX was diagnosed with non-small cell lung cancer. She lived in Canada at the time but chose to go to the Mayo Clinic in Minnesota for radiation treatment since she felt their machines were better. The Mayo Clinic determined that there was a mass of large cell carcinoma, metastic grade 4 which had grown so large that it had fractured her clavicle. They knew this was not the site of the primary tumor but were not able to identify the primary location. There were multiple small tumors scattered throughout the area.

She chose to have radiation treatments of the tumor below the clavical. She then visited the Garvey Institute in Kansas, for what the papers I have call leukapheresis procedure. I know she collected her urine for a number of days and that somehow parts of it were extracted and perhaps parts of blood samples were used also. From this a fluid using the patient’s own tumor material and dendritic cells was made. I assume the study she was a part of was not FDA approved because she had to go to San Jose, Costa Rica to be injected with the finished extract. When she returned home to Canada she followed an organic juicing diet for a period of time.

That was now 15 years ago. My aunt is now 76 years old and still alive and well with no current sign of cancer. Since this time she and my uncle have built a new home in Canada, sold that home, and have moved to Costa Rica full time. She hikes and enjoys all kinds of outdoor activities. They eat a primarily vegetarian diet, supplemented with chicken and fish. They spent a couple weeks with us in California last summer and this fall we hope to make our first trip to visit them in Costa Rica. I have always been surprised that the Garvey Clinic never did follow up questionnaires (sic) with her to see how she was doing since she was such a success story. She proves that even someone with stage 4 metastatic can should not give up hope and should look for treatments that have the potential to help or cure them.

I am sure that information on her diagnosis and treatment must be in your records, but I do have copies of the material she was given, if anyone wants more information.

Sincerely,

XXX

United States Patent 7,749,495
Riordan July 6, 2010
Method for inducing an anti-tumor and anti-cachexia immune response in mammals

Abstract
The invention relates to inducing an immune response toward tumor associated antigens and in particular to the administration of high molecular weight isolates of autologous urine either alone, with adjuvants, or with antigen presenting cells. The antigen presenting cells have been cocultured with isolates of autologous urine. The invention can also be used to treat cachexia in cancer or AIDS patients.

Inventors: Riordan; Neil H. (Chandler, AZ)
Assignee: Aidan, Inc. (Tempe, AZ)
Family ID: 26920848
Appl. No.: 12/126,744
Filed: May 23, 2008

Filed Under: Uncategorized

As many as 32,000 kids infected with drug-resistant TB: report

Posted on March 24, 2014 Written by nhriordan 1 Comment

Reuters report today on drug-resistant tuberculosis. http://www.reuters.com/article/2014/03/23/us-tuberculosis-kids-idUSBREA2M0P520140323

It reminds me of a report 5 years ago from Russia by Erokhin et al. They gave intravenous expanded autologous mesenchymal cells to patients with drug-resistant tuberculosis and saw improvement.1

A new publication just came our of Sweden–a phase I safety trial of the same cell population in patients with multi-drug resistant and extremely drug resistant tuberculosis concluded: “MSCs as an adjunct therapy are safe and can now be explored further for the treatment of patients with MDR or XDR tuberculosis in combination with standard drug regimens. Adjunct treatment with MSCs needs to be evaluated in controlled phase 2 trials to assess effects on immune responses and clinical and microbiological outcomes.2

It would be interesting in someone did a trial expanded allogenic umbilical cord-derived mesenchymal stem cells (huMSCs) vs. autologous bone marrow. huMSCs have been shown to be more effective than autologous and allogenic cells in a number of conditions.

1. Probl Tuberk Bolezn Legk. 2008;(10):3-6.
[Systemic transplantation of autologous mesenchymal stem cells of the bone marrow in the treatment of patients with multidrug-resistant pulmonary tuberculosis].

Abstract
The study undertaken 3 years ago examined the effect of systemic transplantation of autologous mesenchymal stem cells (MSC) in the complex therapy of 27 patients with pulmonary tuberculosis, including 15 patients with multidrug-resistant pulmonary tuberculosis and 12 with extensive drug resistance of Mycobacterium tuberculosis. All the patients were bacteria-discharging persons with disseminated destructive processes in lung tissue, most (n=17) of them had chronic fibrocavernous tuberculosis. In all the patients, previous long specific antituberculous treatment was ineffective or inadequately effective. After systemic MSC transplantation, 16 patients were followed up for 1.5-2 years or more and the remaining 11 patients for at least 6 months. After MSC administration, a positive clinical effect was observed in all 27 cases; bacterial discharge stopped in 20 patients after 3-4 months; resolution of sustained lung tissue cavities further occurred in 11 patients. At present, a persistent remission of a tuberculous process may be stated in 9 of the 16 patients in whom MSCs were transplanted 1.5-2 years, significant positive bacteriological and morphological changes are observed in 6 patients. Thus, inclusion of transplantation of the autologous MSCs propagated in the culture into a course of antituberculous therapy may be a promising procedure for enhancing the efficiency of therapy in patients with resistant forms of pulmonary tuberculosis.

2.Lancet Respir Med. 2014 Feb;2(2):108-22.
Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.
Skrahin A1, Ahmed RK2, Ferrara G3, Rane L4, Poiret T5, Isaikina Y6, Skrahina A7, Zumla A8, Maeurer MJ9.

Filed Under: Uncategorized

Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis

Posted on January 18, 2014 Written by nhriordan 7 Comments

Press release

Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board
Translational Biosciences, a subsidiary of Medistem Panama has received the county’s first clinical trial approval for the treatment of rheumatoid arthritis with human umbilical cord-derived mesenchymal stem cells (MSC) from the Comité Nacional de Bioética de la Investigación (CNEI) Institutional Review Board (IRB).

Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Translational Biosciences Logo
Panama City, Panama (PRWEB) January 14, 2014

Translational Biosciences, a subsidiary of Medistem Panama has received the county’s first clinical trial approval for the treatment of rheumatoid arthritis with human umbilical cord-derived mesenchymal stem cells (MSC) from the Comité Nacional de Bioética de la Investigación Institutional Review Board (IRB).
Rheumatoid Arthritis (RA) is an autoimmune disease in which the patient’s immune system generates cellular and antibody responses to various components of the joint such as type I collagen. As a result of this immune response, not only does joint destruction occur, but also other secondary complications such as pulmonary fibrosis, renal damage, and even heart damage. RA affects approximately 0.5-1% of the population in the United States.
Mesenchymal stem cells harvested from donated human umbilical cords after normal, healthy births possess anti-inflammatory and immune modulatory properties that may relieve RA symptoms. Because they are immune privileged, the recipient’s immune system does not reject them. These properties make MSC interesting candidates for the treatment of rheumatoid arthritis and other autoimmune disorders.
Each patient will receive five intravenous injections of umbilical cord stem cells over the course of 5 days. They will be assessed at 3 months and 12 month primarily for safety and secondarily for indications of efficacy.
The stem cell technology being utilized in this trial was developed by Neil Riordan, PhD, founder of Medistem Panama. The stem cells will be harvested and processed at Medistem Panama’s 8000 sq. ft. laboratory in the prestigious City of Knowledge. They will be administered at the Stem Cell Institute in Panama City, Panama.
The Principle Investigator is Jorge Paz-Rodriguez, MD. Dr. Paz-Rodriguez also serves as the Medical Director at the Stem Cell Institute.
“While this is just the first step, it is our hope that Panama’s rapid emergence as a leader in applied stem cell research will lead to safe, effective treatments for debilitating diseases such as rheumatoid arthritis and serve to benefit all Panamanians who suffer from it in the not-too-distant future,” said Ruben Berocal, M.D., National Secretary of Science, Technology and Innovation (SENACYT). “Oversight by the National Committee for Investigational Bioethics ensures patient safety by demanding ethical transparency and compliance with the highest levels of international standards,” he added.
For detailed information about this clinical trial visit http://www.clinicaltrials.gov. If you are a rheumatoid arthritis patient who has not responded to disease modifying anti-rheumatic drugs (DMARD) for at least 6 months you may qualify for this trial. Please email trials(at)translationalbiosciences(dot)com for more information about how to apply.
About Translational Biosciences
A subsidiary of Medistem Panama Inc., Translational Biosciences was founded solely to conduct clinical trials using adult stem cells and adult stem cell-derived products.
Translational Biosciences Web Site: http://www.translationalbiosciences.com
Email: trials(at)translationalbiosciences(dot)com
About Medistem Panama Inc.
Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.
Medistem Panama Inc.
Ciudad del Saber, Edif. 221 / Clayton
Panama, Rep. of Panama
Phone: +507 306-2601
Fax: +507 306-2601
About Stem Cell Institute Panama
Founded in 2007 on the principles of providing unbiased, scientifically-sound treatment options, the Stem Cell Institute has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor human umbilical cord stem cells to treat: multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases. To-date, the Institute has treated over 2000 patients.
For more information on stem cell therapy:
Stem Cell Institute Website: http://www.cellmedicine.com
Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama
Phone: +1 800 980-STEM (7836) (USA Toll-free) +1 954 636-3390 (from outside USA)
Fax: +1 866 775-3951 (USA Toll-free) +1 775 887-1194 (from outside USA)

Filed Under: Uncategorized Tagged With: arthritis, mesenchymal stem cells, Neil Riordan, Panama, rheumatoid, rheumatoid arthritis, riordan, stem cells

Speaking at Stemso Conference in Freeport, Bahamas February 21, 2014

Posted on January 18, 2014 Written by nhriordan Leave a Comment

Register here: Stemso Website
https://stemso.org/riordan.html>

Screen Shot 2014-01-18 at 3.14.41 PM

Filed Under: Uncategorized

Medistem to be acquired by Intrexon

Posted on December 21, 2013 Written by nhriordan 3 Comments

The company I founded in 2005 is to be acquired by Intrexon for $26 million.
http://finance.yahoo.com/news/intrexon-acquire-medistem-generate-multipotent-154433543.html
GERMANTOWN, Md. and SAN DIEGO, Dec. 20, 2013 (GLOBE NEWSWIRE) — Intrexon Corporation (XON), a leader in synthetic biology, today announced that it has entered into a definitive agreement to acquire, for approximately $26 million, San Diego-based Medistem, Inc. (MEDS) a pioneer in the development of Endometrial Regenerative Cells (“ERC” or “ERCs”), universal donor adult stem cells that stimulate new blood vessel formation and are capable of generating different tissues including heart, brain, pancreas, liver, bone, cartilage and lung. Intrexon intends to employ its integrated synthetic biology platforms to engineer a diverse array of cell-based therapeutic candidates using Medistem’s multipotent ERCs.

Filed Under: Uncategorized

Currently Enrolling Clinical Trials of Islet Transplantation for Type 1 Diabetes

Posted on March 6, 2013 Written by nhriordan 1 Comment

Baylor: http://clinicaltrial.gov/ct2/show/NCT00530686?term=islet+diabetes&rank=59

Ohio: http://clinicaltrial.gov/ct2/show/NCT01705899?term=islet+diabetes&rank=2

U. of Chicago: http://clinicaltrial.gov/ct2/show/NCT01630850?term=islet+diabetes&rank=20

Brussels, Belgium: http://clinicaltrial.gov/ct2/show/NCT00790257?term=islet+diabetes&rank=21

University of Calgary, Canada: http://clinicaltrial.gov/ct2/show/NCT01652911?term=islet+diabetes&rank=32

Milan, Italy: http://clinicaltrial.gov/ct2/show/NCT01652911?term=islet+diabetes&rank=32

University of Illinois at Chicago: http://clinicaltrial.gov/ct2/show/NCT00679042?term=islet+diabetes&rank=61

Argentinian trial of pig islets: http://clinicaltrial.gov/ct2/show/NCT01736228?term=islet+diabetes&rank=79

University of Wisconsin: http://clinicaltrial.gov/ct2/show/NCT00214253?term=islet+diabetes&rank=89

Other resources: Clinical Islet Transplantation Consortium http://www.citisletstudy.org/

Information from NIH on islet transplants: http://diabetes.niddk.nih.gov/dm/pubs/pancreaticislet/

Filed Under: Uncategorized

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »

Neil Riordan, PhD

  • About Neil Riordan, PhD

Follow me on:

  • Facebook
  • Twitter

Recent Posts

  • Amnion-derived cells for regenerative medicine January 27, 2020
  • Vitrification preserves Wharton’s Jelly up to a year January 21, 2020
  • Adipose MSC for Spinal Cord Injury: ASIA Scores Improvement December 4, 2019
  • UCMSC secretions (exosomes) for Perinatal Brain Injury October 3, 2019
  • Immunomodulation of UCMSC in Rheumatoid Arthritis September 26, 2019

Tags

acute liver failure adipose amnion arthritis CD34 diabetes disease dmd duchenne muscular dystrophy fat Frederick Klenner liver lupus mesenchymal mesenchymal stem cells mitochondria mitochondrial neil Neil Riordan opioid opioid tolerance Panama preeclampsia pregnancy rheumatoid rheumatoid arthritis Richard Davis Humphries Richard Humphries riordan spinal cord injury stem cells umbilical cord vitamin C

Copyright © 2023 · Focus Pro Theme on Genesis Framework · WordPress · Log in